Clinical Trials
5 trialsNCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03193853 2023-08-07
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Baylor Research Institute
Phase 2 Completed
NCT02049957 2023-02-08
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Calithera Biosciences, Inc
Phase 2 Completed
NCT02756364 2023-02-08
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
Calithera Biosciences, Inc
Phase 2 Completed
NCT02988986 2021-09-22
ANETT
The Methodist Hospital Research Institute
Phase 2 Completed